How big is Atara Biotherapeutics, Inc.?

As of Jun 18, Atara Biotherapeutics, Inc. has a market capitalization of 53.01 million, classifying it as a Micro Cap company, with net sales of 199.73 million and a net profit of -15.64 million over the last four quarters. The company has shareholder's funds of -97.28 million and total assets of 109.10 million as of Dec 24.

Market Cap: As of Jun 18, Atara Biotherapeutics, Inc. has a market capitalization of 53.01 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Atara Biotherapeutics, Inc. reported net sales of 199.73 million and a net profit of -15.64 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds of -97.28 million and total assets amounting to 109.10 million.

What does Atara Biotherapeutics, Inc. do?

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for severe diseases. As of March 2025, it reported net sales of $98 million and a net profit of $38 million, with a market cap of $53.01 million.

Overview: <BR>Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with severe and life-threatening diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Sales: 98 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 38 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 53.01 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.72 <BR>Return on Equity: 9.94% <BR>Price to Book: -0.96<BR><BR>Contact Details: <BR>Address: 611 Gateway Blvd Ste 900, SOUTH SAN FRANCISCO CA: 94080-7015 <BR>Tel: ['1 650 2788930', '1 805 3959669'] <BR>Fax: 1 302 6365454 <BR>Website: http://www.atarabio.com/

Should I buy, sell or hold Atara Biotherapeutics, Inc.?

Who are in the management team of Atara Biotherapeutics, Inc.?

As of March 2022, the management team of Atara Biotherapeutics, Inc. includes Chairman Ronald Renaud, CEO Dr. Pascal Touchon, Lead Independent Director Dr. Carol Gallagher, and Directors Dr. Maria Roncarolo, Dr. Roy Baynes, Mr. Eric Dobmeier, and Mr. Matthew Fust. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Atara Biotherapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Ronald Renaud, Chairman of the Board<BR>- Dr. Pascal Touchon, President, Chief Executive Officer, and Director<BR>- Dr. Carol Gallagher, Lead Independent Director<BR>- Dr. Maria Roncarolo, Director<BR>- Dr. Roy Baynes, Independent Director<BR>- Mr. Eric Dobmeier, Independent Director<BR>- Mr. Matthew Fust, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Atara Biotherapeutics, Inc. overvalued or undervalued?

As of May 4, 2021, Atara Biotherapeutics, Inc. is considered risky and overvalued based on its financial metrics, despite a strong one-year return of 53.37%, due to poor long-term performance and unfavorable comparisons with peers.

As of 4 May 2021, the valuation grade for Atara Biotherapeutics, Inc. moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of -1.14, an EV to EBITDA of 62.71, and an EV to Sales of 0.51. In comparison, peers such as Fusion Pharmaceuticals, Inc. have a P/E ratio of -17.5788 and an EV to EBITDA of -15.5851, while Emergent BioSolutions, Inc. shows a more attractive P/E of 2.9017 and an EV to EBITDA of 3.8058.<BR><BR>Despite a strong one-year return of 53.37% compared to the S&P 500's 17.14%, the company's long-term performance has been significantly poor, with a three-year return of -88.05% versus the S&P 500's 70.41%. This suggests that while there may be short-term gains, the overall valuation remains questionable, reinforcing the view that Atara Biotherapeutics is overvalued.

Is Atara Biotherapeutics, Inc. technically bullish or bearish?

As of August 12, 2025, Atara Biotherapeutics, Inc. shows a bullish technical trend with strong MACD and moving averages, despite mixed signals from Dow Theory and OBV, having outperformed the S&P 500 over the past year but underperformed year-to-date.

As of 12 August 2025, the technical trend for Atara Biotherapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe. However, the Dow Theory presents a mildly bearish outlook on both weekly and monthly timeframes, and the On-Balance Volume (OBV) is mildly bearish on the weekly but bullish on the monthly.<BR><BR>In terms of returns, the stock has outperformed the S&P 500 over the past year with a return of 53.37% compared to the S&P 500's 17.14%, but it has underperformed year-to-date with a return of -9.32% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish, driven primarily by the bullish signals in MACD and moving averages, despite some mixed indicators from Dow Theory and OBV.